The UC Irvine School of Medicine recognized the 2024 best mentors and Elizabeth Head, PhD, Professor and Vice Chair of Research in the Department of Pathology and Laboratory Medicine was…
Lee mas
For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions…
Lee mas
Jessica Noche, PhD, a postdoctoral scholar and REMIND co-chair recently published an article in the Journal of Neuroscience with UCI MIND faculty, Craig Stark, PhD, and Elizabeth Head, PhD, on…
Lee mas
As we celebrate Women’s History Month this March, we also find ourselves at a historic moment in scientific inquiry for women’s health research. Today, nearly two-thirds of Americans with Alzheimer’s…
Lee mas
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein…
Lee mas
Ahmad Sajjadi, MD, PhD, a UCI Neurologist and UCI MIND faculty member was interviewed live on NBC Los Angeles about the recent announcement that talk show host Wendy Williams…
Lee mas
The LA Times recently published a fairly negative appraisal of the construct of preclinical Alzheimer’s disease (AD). The article described the recent effort by an international committee to update diagnostic…
Lee mas
Biogen, the maker of aducanumab has announced that it will terminate the Phase 4 trial required by the FDA for aducanumab, the monoclonal antibody against beta amyloid that received accelerated…
Lee mas
The medications have not been widely tested in Black people with the disease, underscoring stark — and persistent — disparities ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford…
Lee mas
Black people know intrinsically about the myriad of life areas negatively impacted by the fact that the myth of white supremacy is baked into the foundations of all American institutions.…
Lee mas